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Abstract
Objective The goal of this study was to retrospectively
collect data about treatment outcomes in patients diagnosed
with Stenotrophomonas maltophilia bacteraemia over a
period of 20 years and evaluate these data with respect to
the efficacy of treatment options.
Methods The setting was a 700-bed tertiary care hospital
in a large urban area. Hospital databases and medical
records provided information about episodes of S. malto-
philia, patient characteristics and treatment outcomes.
Patients with at least one positive blood culture for S.
maltophilia were included in the study. Data were analysed
with respect to clinical improvement and mortality
B30 days after the onset of infection. We compared patient
characteristics, laboratory values and treatments by using
the Chi-square or Fisher’s exact tests and the Mann–
Whitney test.
Results We investigated 27 patients with S. maltophilia
bacteraemia. The focus of infection was a central venous
catheter in 18 (67 %) cases. The 30-day mortality rate was
11 %. All patients who were treated with an antibiotic that
was effective in vitro against the pathogen recovered
clinically and survived C30 days after the onset of infec-
tion. The most frequently used antibiotic was trimetho-
prim–sulfamethoxazole administered alone or in
combination with a fluoroquinolone.
Conclusions Despite the fact that S. maltophilia is resis-
tant to multiple antibiotics, the prognosis for patients with
S. maltophilia bacteraemia is good when they are treated
with antibiotics that are effective against this pathogen
in vitro.
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Introduction
Stenotrophomonas maltophilia, a Gram-negative, non-fer-
mentative bacillus, is increasingly being recognised as a
cause of nosocomial infections [1], but the treatment of a S.
maltophilia infection is challenging. This is primarily due
to the inherent resistance of S. maltophilia to multiple
classes of antibiotics, including beta-lactams, aminogly-
cosides and carbapenems [2]. Given the lack of randomised
clinical trials to test treatment options for S. maltophilia
bacteraemia, current recommendations for treatment are
based mostly on in vitro susceptibility tests and expert
opinion. Trimethoprim–sulfamethoxazole (TMP/SMX) is
the usual drug of choice because of its excellent in vitro
activity against S. maltophilia. A high dose of TMP
(15 mg/kg/day) is generally recommended to reduce the
risk of emerging resistance to TMP/SMX [1]. However,
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allergic reactions and toxicities related to the administra-
tion of TMP/SMX in patients limit the use of this drug in
clinical practice [3]. Fluoroquinolones are an alternative
option for treatment, if the pathogen is shown to be sus-
ceptible to the specific antimicrobial in vitro [1, 2]. The
reported mortality rates of S. maltophilia infections are
high, i.e. 15–62 %. However, most studies did not focus on
therapeutic aspects [4–7].
The goal of this study was to retrospectively collect
information about the treatment of S. maltophilia bacter-
aemia and its outcomes over a period of 20 years in a
single-centre setting and to describe the effectiveness of the
treatment.
Patients and methods
The setting for this study was a 700-bed tertiary care
hospital that is associated with a university in a large urban
area of approximately half a million inhabitants. To ret-
rospectively study outcomes for the treatment of S.
maltophilia bacteraemia, we chose to review all episodes of
S. maltophilia bacteraemia over a 20-year period beginning
in January 1993 and ending in January 2013. Data were
collected by first reviewing the microbiology database at
the University Hospital Basel to identify episodes of S.
maltophilia bacteraemia and then by cross-checking this
information with data in the databases of the Clinical
Microbiology Laboratory and the Infection Control Divi-
sion at the hospital to identify the specific patient cases
associated with these episodes of bacteraemia. All patients
who had one or more blood cultures that were positive for
S. maltophilia were included in the study. Hospital medical
records provided information about patient demographic
characteristics, co-morbidities, the focus of the infection
attributed to S. maltophilia, the number of positive blood
cultures, time to positivity of blood cultures, the suscepti-
bility of the identified pathogen in each case to specific
antimicrobial agents in vitro, and the type and duration of
both empirical and targeted antibiotic therapy. Treatment
outcomes were assessed with respect to clinical improve-
ment and 30-day mortality in the patients.
Empirical therapy was defined as the administration of
antibiotics at the onset of symptoms of bacteraemia. Ade-
quate treatment was defined as the targeted administration
of at least one antimicrobial agent to which S. maltophilia
was susceptible in vitro.
Nosocomial infections and sepsis were defined accord-
ing to the Centers for Disease Control and Prevention
(CDC) and international consensus definitions [8]. In brief,
a positive blood culture with S. maltophilia was defined as
‘catheter-related’ if a central venous line was in place
C48 h and S. maltophilia was cultured from the catheter tip
with more than 15 colony-forming units. We used the term
‘catheter-associated’ for cases having a central venous
catheter for 48 h or more and without any evidence for
another source.
A patient was considered immunosuppressed if they
were receiving chemotherapy or radiotherapy for malig-
nancies, immunosuppressive therapies with a daily dose
C10 mg prednisolone-equivalent steroid, monoclonal
antibodies, antimetabolite drugs or T cell inhibitors within
the preceding 30 days of the positive blood culture. Neu-
tropaenia (absolute neutrophil granulocyte cell count of
\0.5 9 109/L) at the time of bacteraemia was also defined
as immunosuppression.
The S. maltophilia isolates from infection episodes that
were reported in the microbiology database had been
detected in the Clinical Microbiology Laboratory by using
standard assays, including API20 NE (bioMe´rieux,
France), VITEK 2 (bioMe´rieux, France) and MALDI
Biotyper (Bruker Daltonik, Germany), or, in special cases,
by sequencing of the 16S rRNA gene. For susceptibility
testing in vitro, the commercial systems Micronaut (Mer-
lin, Germany), VITEK 2 (bioMe´rieux, France) or Etest
(bioMe´rieux, France) were used [9]. From 1993 through
May 2011, the results for antimicrobial susceptibility were
interpreted according to the standards of the Clinical and
Laboratory Standards Institute [CLSI, formerly National
Committee for Clinical Laboratory Standards (NCCLS)].
From June 2011 onwards, they were interpreted according
to the standards of the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST).
Patient characteristics, laboratory values and treatments
were compared by using the Chi-square or Fisher’s exact
tests for categorical variables and the Mann–Whitney test
for continuous variables. Analyses were performed by
using SPSS version 21 software (SPSS Inc., USA).
To more definitively characterise treatment outcomes,
patients were assigned to one of two groups. The two
groups were defined by the adequacy of treatment.
The study was approved by the Ethical Committee of
Basel (178/13).
Results
S. maltophilia was identified in almost 1,000 microbio-
logical samples over the 20-year study period. From these
data, we identified 29 patients with at least one positive
blood culture for S. maltophilia. Two patients were
excluded from the study because detailed medical data
were not available for them. Table 1 shows the baseline
patient characteristics for the two treatment groups to
which patients were assigned: the group which received
adequate treatment and the group which did not receive
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adequate treatment. Table 2 describes in more detail the
therapeutic treatment for each patient.
All of the patients had multiple co-morbidities, and 12
(44 %) of them were immunosuppressed. Twenty-five
(93 %) patients had been seen by a specialist in the
Infectious Diseases Consultant Service. All bacteraemia
episodes except for one were nosocomial infections. The
most common focus of bacteraemia was a central line,
followed by a focus in the respiratory tract (Table 1).
Detailed data on central venous catheter insertion and
removal could be analysed in 17 of 18 patients. The
duration of central venous catheter use was 15 days
(median; IQR 12–21) at the diagnosis of S. maltophilia in
blood culture. After obtaining blood culture results, cath-
eters were removed within 1 day (median; IQR 0–3). The
majority of patients had also been diagnosed with sepsis
(24; 89 %), of whom seven had septic shock. Most patients
(78 %) had been treated with broad-spectrum antibiotics
within the 30 days prior to the onset of S. maltophilia
bacteraemia symptoms. The median number of S. malto-
philia-positive blood cultures was 1 (IQR 1–2), and the
median time to positivity was 24 h in the blood culture
system. S. maltophilia was identified as the single pathogen
present in cultures for 18 (67 %) of the patients. All iso-
lates of S. maltophilia were susceptible to TMP/SMX, 12
isolates (41 %) were intermediate susceptible or resistant
to ciprofloxacin and only one isolate was resistant to lev-
ofloxacin from the 17 isolates tested. Six patients were
treated with antimicrobial agents that were not active
in vitro. In this latter group, patients 15, 24 and 27
(Table 2) died before their treatment was changed as rec-
ommended by the specialist in infectious diseases, and
patients 5, 11 and 16 (Table 2) survived their bacteraemia
episodes. Ventilator-associated pneumonia (VAP) was
identified as the source of bacteraemia in two out of three
patients (patients 24 and 27) with fatal outcome. For
patients 5 and 16 (Table 2), central catheters were removed
and no further antibiotic treatment was administered. The
positive blood culture of patient 11 (Table 2) was retro-
spectively considered as a contamination.
Of the 21 patients who were defined as having received
adequate treatment, 16 (76 %) were treated with TMP/
SMX alone, two were treated with TMP/SMX in combi-
nation with fluoroquinolones and three were treated with
fluoroquinolones alone. Detailed information about the
dosages and side effects of TMP/SMX monotherapy for
patients in this study is shown in Table 3.
The 30-day mortality rate of patients with S. maltophilia
bacteraemia was 11 % (3 of 27 patients). All patients who
received treatment with an antibiotic shown to be effective
Table 1 Baseline characteristics of 27 patients diagnosed with
Stenotrophomonas maltophilia bacteraemia in a single-centre study
over a period of 20 years
Variable Group
receiving
adequate
treatmenta
(n = 21)
Group not
receiving
adequate
treatment
(n = 6)
p-
Value
Median age in years
(IQR)
59 (43–69) 72 (71–77) \0.001
Number of males 9 (43 %) 3 (50 %) 0.756
Number of patients with:
Comorbidity
Cardiovascular
disease
9 (43 %) 4 (66 %) 0.352
Renal impairmentb 5 (24 %) 3 (50 %) 0.245
Diabetes mellitus 3 (14 %) 2 (33 %) 0.318
Immunosuppression 9 (43 %) 3 (50 %) 0.829
Sepsis 19 (90 %) 5 (83 %) 0.623
Polymicrobial
infection
8 (38 %) 1 (17 %) 0.617
Median length (in
days) of hospital stay
prior to onset of
bacteraemia (IQR)
10 (6–13) 18 (5–38) 0.387
ICU stay within
30 days
4 (19 %) 5 (83 %) 0.004
Prior hospitalisation
within 30 days
8 (38 %) 3 (50 %) 0.662
Number of patients with a bacteraemia focus that was:
Central line 15 (71 %) 3 (50 %) 0.326
Pneumonia 4 (29 %) 3 (50 %) 0.289
Otherc 2 (10 %) 0 1.000
Median C-reactive
protein in mg/l (IQR)
116 (77–229) 121 (63–165) 0.887
Median creatinine in
lmol/l (IQR)
76 (58–93) 102 (97–108) 0.307
Median number of
hours between onset
of symptoms and a
positive blood culture
(IQR)
24 (22–29) 24 (22–24) 0.563
Number of patients
who died within
30 days after onset of
symptoms of
bacteraemia
0 3 (50 %) 0.007
IQR interquartile range, ICU intensive care unit
a Adequate treatment: defined as the targeted administration of at
least one antimicrobial agent to which S. maltophilia was susceptible
in vitro
b Renal impairment: defined as a creatinine clearance of \60 ml/min
c Other: urinary tract infection (patient 2), surgical site infection
(patient 25)
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Table 2 Focus of infection and type of antibiotic treatment for 27 patients diagnosed with S. maltophilia bacteraemia
Patient Age
(years)
Gender Focus of S. maltophilia
bacteraemia/associated clinical
condition
Empirical therapy
antimicrobials
Targeted
therapy
antimicrobials
Duration of
targeted therapy
(days)
Survived C30 days?
1 63 F CLR/metastatic breast cancer Cefepime TMP/SMX 13 Yes
2 66 M Urosepsis/bladder urothelial
carcinoma
Ciprofloxacin TMP/SMX 18 Yes
3 46 F CLR/severe cellulitis Piperacillin/
tazobactam
TMP/SMX 14 Yes
4 60 F VAP/necrotising fasciitis Piperacillin/
tazobactam
TMP/SMX 14 Yes
5 67 F CLA/secondary amyloidosis Imipenem – – Yes
6 76 F CLA/abdominal injury,
multimorbidity
Ciprofloxacin TMP/SMX 14 Yes
7 59 M CLA/septic shock with
Staphylococcus aureus
Piperacillin/
tazobactam
TMP/SMX 4 Yes
8 30 M CLR/intravenous drug use,
community-acquired sepsis
Piperacillin/
tazobactam
Ciprofloxacin 14 Yes
9 58 M CLA/multiple myeloma TMP/SMX TMP/SMX,
ciprofloxacin
17 Yes
10 50 M Pneumonia/severe pulmonary
fibrosis
Piperacillin/
tazobactam
TMP/SMX,
levofloxacin
17 Yes
11 71 M Pneumonia/bowel ischaemia
and resection/hypovolaemic
shock
Piperacillin/
tazobactam,
metronidazole
– – Yes
12 15 F CLR/polytrauma Cefepime TMP/SMX 13 Yes
13 48 M CLA/acute myeloid leukaemia Meropenem TMP/SMX 14 Yes
14 69 M Pneumonia/prostate cancer Piperacillin/
tazobactam
Ciprofloxacin 14 Yes
15 71 M CLA/metastatic prostate
carcinoma
Amoxicillin/
clavulanate
– – No
16 72 M CLA/hepatic abscess Vancomycin,
tobramycin
– – Yes
17 71 M CLA/parkinsonism and severe
pneumonia
Piperacillin/
tazobactam
TMP/SMX 9 Yes
18 25 F CLA/acute lymphoblastic
leukaemia
TMP/SMX TMP/SMX 14 Yes
19 76 M Pneumonia/urinary tract
infection
Piperacillin/
tazobactam
Ciprofloxacin 14 Yes
20 71 F CLA/complicated hip prosthesis
infection
TMP/SMX,
ertapenem
TMP/SMX 14 Yes
21 80 F CLR/Staphylococcus aureus
sepsis
Piperacillin/
tazobactam
TMP/SMX 15 Yes
22 68 F CLA/acute myeloid leukaemia Ciprofloxacin TMP/SMX 16 Yes
23 44 F CLA/HIV, endometrial cancer Piperacillin/
tazobactam
TMP/SMX 20 Yes
24 80 F VAP/myocardial infarction and
brain death
– – – No
25 39 F Surgical site infection/distortion
trauma
Piperacillin/
tazobactam
TMP/SMX 14 Yes
26 35 F CLA/complications from
Caesarean section
Amoxicillin/
clavulanate
TMP/SMX 14 Yes
27 78 F VAP/chronic heart failure Piperacillin/
tazobactam
– – No
F female, M male, TMP/SMX trimethoprim–sulfamethoxazole, CLR central line-related, CLA central line-associated, VAP ventilator-associated
pneumonia, HIV human immunodeficiency virus
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against S. maltophilia in vitro clinically recovered and
none of them died in the 30-day period following the onset
of the infection. No differences in outcomes were observed
with respect to the use of different TMP/SMX dosages.
Discussion
Various studies have reported a mortality rate for S.
maltophilia infections of 15–29 % and the mortality rate
for bacteraemia was even higher, reaching up to 62 % [4–
7, 10]. However, in this study, we observed an excellent
prognosis with clinical improvement and no 30-day mor-
tality when adequate treatment with TMP/SMX and/or a
fluoroquinolone was provided, even when the daily TMP
dose was lower than 15 mg/kg [1]. The most striking
finding of the current analysis was a zero mortality rate in
adequately treated patients diagnosed with S. maltophilia
bacteraemia. We identified four factors that might have
contributed to these excellent outcomes for treatment.
First, the S. maltophilia isolates in this study were all
susceptible to TMP/SMX in vitro. This is in agreement
with an overall low rate of TMP/SMX resistance (3.7 %)
for S. maltophilia in Switzerland (http://www.anresis.ch).
This is in contrast to higher rates of TMP/SMX resistance
reported in other European countries and in North America
[11].
Second, the use of TMP/SMX in most of our patients
very likely contributed to the positive outcomes in this
study, given that TMP/SMX is known to be the most
efficient antimicrobial for either monotherapy or combi-
nation therapy against susceptible S. maltophilia isolates
[1, 2]. Newer fluoroquinolones, minocycline or tigecycline
might be future alternatives to combat emerging TMP/
SMX resistance; however, the selection of resistant S.
maltophilia strains with the use of quinolones remains a
concern [2]. The administration of TMP/SMX can be
associated with adverse events such as neutropaenia,
hepatopathy or decreased tubular secretion of creatinine
and also with more uncommon severe skin diseases such as
Stevens–Johnson syndrome or with central nervous system
side effects [3]. However, the complication rate in this
study was low. It is, therefore, noteworthy that the average
dose of TMP used in the study was lower than the normally
recommended dose of 15 mg/kg body weight per day. It is
especially noteworthy in light of the low toxicity rate
among these patients and the generally excellent outcomes.
However, prospective, well-controlled and larger studies
are required in order to confirm these retrospective findings
on TMP/SMX dosages for treating S. maltophilia
bacteraemia.
Third, the patients in the group whose antimicrobial
therapy conformed with our definition of adequate treat-
ment were somewhat younger (p \ 0.001) and also
required less time in the intensive care unit (ICU) than
other patients in the study whose therapy did not conform
to the definition of adequate treatment (p = 0.004), which
indicates lower morbidity in the group.
Fourth, a central line was the focus identified in two-
thirds of the cases, which has been shown in earlier studies
to be associated with a lower mortality rate [5, 6].
The limitations of the study are the rather small number
of cases and the retrospective design of the study. The
strengths of the study include the amount of information
that was provided by the detailed work-ups of patients with
S. maltophilia bacteraemia, in particular the information
about therapeutic aspects and outcome in each case. In
addition, the involvement of an infectious disease specialist
in all but two cases provided specialised and detailed data
about the cases that are still useful years after the events
occurred.
In conclusion, S. maltophilia bacteraemia is a serious
condition, but it appears to have a low mortality rate when
central lines are removed as quickly as possible after the
onset of infection and patients receive adequate treatment,
preferably treatment with TMP/SMX, if the identified
pathogen is shown to be susceptible to this antimicrobial
agent in vitro.
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Table 3 Details about TMP/SMX monotherapy in 16 patients diag-
nosed with S. maltophilia bacteraemia
Median number of days of treatment with TMP/
SMX (IQR)
13 (8–14.5)
Median daily dose of trimethoprim (in mg/kg) at
the end of the treatment period (IQR)
6.6 (4.2–13.2)
Number of patients to whom TMP/SMX was being
administered at a lower than recommended high
dose (\5 mg TMP/kg; TID) [1] at the start of the
treatment period (patients 1, 2, 3, 4, 6, 7, 12, 17,
18, 22 and 26 in Table 2)
11 (69 %)
Number of patients for whom a dose reduction was
required because of a reaction to the medication
(renal toxicity; patients 2 and 13 in Table 2)
2 (13 %)
Number of patients for whom TMP/SMX was
changed to fluoroquinolones because of treatment
complications (i.e. delirium; patient 10 in
Table 2)
1 (6 %)
Median percentage of the recommended dose (5 mg
TMP/kg; TID) that was adjusted to the weight and
renal function of the patient (IQR)
44.2 %
(33.1–70.5)
Median percentage of normal dose (5 mg TMP/kg;
BID) that was adjusted to the weight and renal
function of the patient (IQR)
66.3 %
(49.7–105.8)
TMP/SMX trimethoprim–sulfamethoxazole, IQR interquartile range
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